Asian Spectator


The Times

.

Mangroves Documentary Premieres, Exploring How Cities and Wetlands Coexist

SHENZHEN, CHINA – Media OutReach Newswire – 17 November 2026 – Guangdong Radio and Television has unveiled Mangroves, a three-part ecological documentary filmed in 4K ultra-high de...

Barcelona Bridal Fashion Week presents the world's first fashi...

BARCELONA, Spain, April 12, 2022 /PRNewswire-AsiaNet/ -- - The firm will exhibit its creations at Barcelona Bridal NightThe fashion artists Viktor Horsting and Rolf Snoeren will present the ...

CSafe and BioLife Solutions, Inc. announce partnership to expa...

MONROE, Ohio and BOTHELL, Wash., Oct. 11, 2022 /PRNewswire-AsiaNet/ -- -- CSafe joins BioLife's global partner network of cold chain solution providers using the evo (R) cold chain managemen...

Fujitsu Concludes Share Transfer Agreement Concerning the Mobile Phone Retail Store Business

TOKYO, Aug 31, 2020 - (JCN Newswire) - Fujitsu Limited today announced that it has agreed to transfer its shares in the new company which will succeed the mobile phone retail store business...

AsiaTokenFund Group Partners with 1MAX.com to Launch Curated Crypto Trading Platform

TORTOLA, BRITISH VIRGIN ISLAND - Media OutReach Newswire - 3 April 2026 - AsiaTokenFund Group today announced a strategic partnership with 1MAX.com to jointly venture and launch a next-gen...

Litmaps closes $125K in seed-stage investment from Quidnet Ven...

SAN FRANCISCO, Sept. 2, 2021 /PRNewswire-AsiaNet/ -- Litmaps, a Science software company based in Wellington, New Zealand has received NZ$125,000 in funding from Quidnet Ventures, a New Zeal...

Elekta Unity, World's First High-Field MR-Linac, Receives CE Mark

STOCKHOLM, June 18, 2018 /PRNewswire-AsiaNet/ -- New radiation therapy system will now be implemented clinically in Europe, ushering in a transformation in precision and personalized cancer ...

Juyeon Lee, Head of Xsolla APAC: Xsolla Buy Button Designed to Reduce Friction and Drive More Revenue Online

Surge in New Partnerships Across Japan and India Reflects Growing Interest in Alternative PaymentsSEOUL, SOUTH KOREA - Media OutReach Newswire - 13 June 2025 -Game developers increasingly s...

Royal Canadian Mint Reports Profits and Performance for 2020

OTTAWA, ON, May 1, 2021 /PRNewswire-AsiaNet/-- The Royal Canadian Mint (the "Mint") is pleased to announce its financial results for 2020 that provide insight into our activities, the market...

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

TOKYO, Mar 26, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).

This application is based on data from a multicenter, open-label, single-arm Phase II clinical study (study 205) conducted in Japan for patients with relapsed or refractory CTCL or PTCL to evaluate the efficacy and safety of this agent.

This study achieved the primary endpoint and exceeded a predetermined threshold with statistical significance: the objective response rate (ORR) of CTCL and PTCL patients in total (n=36) was 36.1% (95% confidence interval (CI): 20.8-53.8). The ORRs of each subtype were 31.6% (95% CI:12.6-56.6) for CTCL (n=19) and 41.2% (95%CI: 18.4-67.1) for PTCL (n=17).

The five most frequent adverse events observed in this study were increased aspartate aminotransferase (AST) (89.2%), increased alanine aminotransferase (ALT) (86.5%), hypoalbuminaemia (70.3%), lymphopenia (70.3%), and pyrexia (51.4%).

Denileukin diftitox (genetic recombinant) is a fusion protein of the receptor-binding portion of interleukin-2 (IL-2) and diphtheria toxin that specifically binds to the IL-2 receptor on the surface of tumoral lymphocyte. The antitumor effect of denileukin diftitox depends on the intracellular delivery of diphtheria toxin which inhibits protein synthesis and induces cell death. The agent has been evaluated as a drug with high medical need by the "Study Group for Unapproved Drugs/Off-Label Drugs for High Medical Needs"(1), and Eisai has been requested to develop it by the Ministry of Health, Labour and Welfare.

Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.

(1) The Study Group set up within the Ministry of Health, Labour and Welfare with the purpose of contributing to enhancing the development of drugs and indications that have not been approved in Japan (unapproved drugs/off-label drugs) by pharmaceutical companies. In addition to evaluating the medical needs of unapproved drugs/off-label drugs, their responsibilities include evaluating the applicability of the drug to an Application with Public Knowledge, and the adequacy of additional clinical studies that need to be conducted for filing applications for approval, and so on.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegaluk casinos not on gamstophttps://www.capitolcitycinema.org/grandpashabet girisStreamEastStreamEastjojobet